Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer

Matthew Saldana, Kacey VanderVorst, Anastasia L. Berg, Hyun Lee, Kermit L Carraway

Research output: Contribution to journalReview article

Abstract

The ubiquitin system regulates diverse biological processes, many involved in cancer pathogenesis, by altering the ubiquitination state of protein substrates. This is accomplished by ubiquitin ligases and deubiquitinases (DUBs), which respectively add or remove ubiquitin from substrates to alter their stability, activity, localization and interactions. While lack of catalytic activity makes therapeutic targeting of ubiquitin ligases difficult, DUB inhibitors represent an active area of research and the identification of cancer-associated DUBs may lead to the development of novel therapeutics. A growing body of literature demonstrates that the DUB Otubain 1 (OTUB1) regulates many cancer-associated signaling pathways including MAPK, ERa, epithelial-mesenchymal transition (EMT), RHOa, mTORC1, FOXM1 and P53 to promote tumor cell survival, proliferation, invasiveness and therapeutic resistance. In addition, clinical studies have associated elevated OTUB1 expression with high grade, invasiveness and metastasis in several tumor types including lung, breast, ovarian, glioma, colon and gastric. Interestingly, in addition to catalytic DUB activity, OTUB1 displays a catalytic-independent, non-canonical activity where it inhibits the transfer of ubiquitin onto protein substrates by sequestration of E2 ubiquitin-conjugating enzymes. The aim of this review is to describe the canonical and non-canonical activities of OTUB1, summarize roles for OTUB1 in cancer-associated pathways and discuss its potential therapeutic targeting.

LanguageEnglish (US)
PagesR1-R14
JournalEndocrine-related cancer
Volume26
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ubiquitin
Neoplasms
Ligases
Ubiquitin-Conjugating Enzymes
Biological Phenomena
Epithelial-Mesenchymal Transition
Ubiquitination
Therapeutics
Glioma
Deubiquitinating Enzymes
Cell Survival
Stomach
Colon
Proteins
Breast
Cell Proliferation
Neoplasm Metastasis
Lung
Research

Keywords

  • DUB inhibitor
  • E2 enzyme
  • metastasis
  • OTUB1
  • ubiquitin ligase

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

Otubain 1 : a non-canonical deubiquitinase with an emerging role in cancer. / Saldana, Matthew; VanderVorst, Kacey; Berg, Anastasia L.; Lee, Hyun; Carraway, Kermit L.

In: Endocrine-related cancer, Vol. 26, No. 1, 01.01.2019, p. R1-R14.

Research output: Contribution to journalReview article

Saldana, Matthew ; VanderVorst, Kacey ; Berg, Anastasia L. ; Lee, Hyun ; Carraway, Kermit L. / Otubain 1 : a non-canonical deubiquitinase with an emerging role in cancer. In: Endocrine-related cancer. 2019 ; Vol. 26, No. 1. pp. R1-R14.
@article{cc95900f4bef4b1e8fe79560f108b45e,
title = "Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer",
abstract = "The ubiquitin system regulates diverse biological processes, many involved in cancer pathogenesis, by altering the ubiquitination state of protein substrates. This is accomplished by ubiquitin ligases and deubiquitinases (DUBs), which respectively add or remove ubiquitin from substrates to alter their stability, activity, localization and interactions. While lack of catalytic activity makes therapeutic targeting of ubiquitin ligases difficult, DUB inhibitors represent an active area of research and the identification of cancer-associated DUBs may lead to the development of novel therapeutics. A growing body of literature demonstrates that the DUB Otubain 1 (OTUB1) regulates many cancer-associated signaling pathways including MAPK, ERa, epithelial-mesenchymal transition (EMT), RHOa, mTORC1, FOXM1 and P53 to promote tumor cell survival, proliferation, invasiveness and therapeutic resistance. In addition, clinical studies have associated elevated OTUB1 expression with high grade, invasiveness and metastasis in several tumor types including lung, breast, ovarian, glioma, colon and gastric. Interestingly, in addition to catalytic DUB activity, OTUB1 displays a catalytic-independent, non-canonical activity where it inhibits the transfer of ubiquitin onto protein substrates by sequestration of E2 ubiquitin-conjugating enzymes. The aim of this review is to describe the canonical and non-canonical activities of OTUB1, summarize roles for OTUB1 in cancer-associated pathways and discuss its potential therapeutic targeting.",
keywords = "DUB inhibitor, E2 enzyme, metastasis, OTUB1, ubiquitin ligase",
author = "Matthew Saldana and Kacey VanderVorst and Berg, {Anastasia L.} and Hyun Lee and Carraway, {Kermit L}",
year = "2019",
month = "1",
day = "1",
doi = "10.1530/ERC-18-0264",
language = "English (US)",
volume = "26",
pages = "R1--R14",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "1",

}

TY - JOUR

T1 - Otubain 1

T2 - Endocrine-Related Cancer

AU - Saldana, Matthew

AU - VanderVorst, Kacey

AU - Berg, Anastasia L.

AU - Lee, Hyun

AU - Carraway, Kermit L

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The ubiquitin system regulates diverse biological processes, many involved in cancer pathogenesis, by altering the ubiquitination state of protein substrates. This is accomplished by ubiquitin ligases and deubiquitinases (DUBs), which respectively add or remove ubiquitin from substrates to alter their stability, activity, localization and interactions. While lack of catalytic activity makes therapeutic targeting of ubiquitin ligases difficult, DUB inhibitors represent an active area of research and the identification of cancer-associated DUBs may lead to the development of novel therapeutics. A growing body of literature demonstrates that the DUB Otubain 1 (OTUB1) regulates many cancer-associated signaling pathways including MAPK, ERa, epithelial-mesenchymal transition (EMT), RHOa, mTORC1, FOXM1 and P53 to promote tumor cell survival, proliferation, invasiveness and therapeutic resistance. In addition, clinical studies have associated elevated OTUB1 expression with high grade, invasiveness and metastasis in several tumor types including lung, breast, ovarian, glioma, colon and gastric. Interestingly, in addition to catalytic DUB activity, OTUB1 displays a catalytic-independent, non-canonical activity where it inhibits the transfer of ubiquitin onto protein substrates by sequestration of E2 ubiquitin-conjugating enzymes. The aim of this review is to describe the canonical and non-canonical activities of OTUB1, summarize roles for OTUB1 in cancer-associated pathways and discuss its potential therapeutic targeting.

AB - The ubiquitin system regulates diverse biological processes, many involved in cancer pathogenesis, by altering the ubiquitination state of protein substrates. This is accomplished by ubiquitin ligases and deubiquitinases (DUBs), which respectively add or remove ubiquitin from substrates to alter their stability, activity, localization and interactions. While lack of catalytic activity makes therapeutic targeting of ubiquitin ligases difficult, DUB inhibitors represent an active area of research and the identification of cancer-associated DUBs may lead to the development of novel therapeutics. A growing body of literature demonstrates that the DUB Otubain 1 (OTUB1) regulates many cancer-associated signaling pathways including MAPK, ERa, epithelial-mesenchymal transition (EMT), RHOa, mTORC1, FOXM1 and P53 to promote tumor cell survival, proliferation, invasiveness and therapeutic resistance. In addition, clinical studies have associated elevated OTUB1 expression with high grade, invasiveness and metastasis in several tumor types including lung, breast, ovarian, glioma, colon and gastric. Interestingly, in addition to catalytic DUB activity, OTUB1 displays a catalytic-independent, non-canonical activity where it inhibits the transfer of ubiquitin onto protein substrates by sequestration of E2 ubiquitin-conjugating enzymes. The aim of this review is to describe the canonical and non-canonical activities of OTUB1, summarize roles for OTUB1 in cancer-associated pathways and discuss its potential therapeutic targeting.

KW - DUB inhibitor

KW - E2 enzyme

KW - metastasis

KW - OTUB1

KW - ubiquitin ligase

UR - http://www.scopus.com/inward/record.url?scp=85056255031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056255031&partnerID=8YFLogxK

U2 - 10.1530/ERC-18-0264

DO - 10.1530/ERC-18-0264

M3 - Review article

VL - 26

SP - R1-R14

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 1

ER -